(Q37268930)

19 August 2017

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone (English)

1 reference

19 August 2017

0 references

1 reference

1 reference

13

David Dingli

1 reference

19 August 2017

7

Angela Dispenzieri

1 reference

19 August 2017

20

Robert A Kyle

1 reference

19 August 2017

4

Martha Q Lacy

1 reference

19 August 2017

16

Stephen J Russell

1 reference

19 August 2017

22

S Vincent Rajkumar

1 reference

19 August 2017

10

Morie A Gertz

1 reference

19 August 2017

6

Suzanne R Hayman

1 reference

19 August 2017

18

Steven R Zeldenrust

1 reference

19 August 2017

15

John A Lust

1 reference

19 August 2017

8

Francis Buadi

1 reference

19 August 2017

2

Shaji Kumar

1 reference

19 August 2017

5

Thomas E Witzig

1 reference

19 August 2017

1

Prashant Kapoor

1 reference

19 August 2017

9

P Leif Bergsagel

1 reference

19 August 2017

14

Craig B Reeder

1 reference

19 August 2017

17

Vivek Roy

1 reference

19 August 2017

12

Joseph R Mikhael

1 reference

19 August 2017

21

Philip R Greipp

1 reference

19 August 2017

Rafael Fonseca

3

0 references

author name string

Robert J Dalton

series ordinal

11

1 reference

PMCID

2713462

19 August 2017

A Keith Stewart

series ordinal

19

1 reference

PMCID

2713462

19 August 2017

language of work or name

English

0 references

publication date

26 March 2009

1 reference

19 August 2017

1 reference

19 August 2017

114

1 reference

19 August 2017

518-521

1 reference

19 August 2017

3

1 reference

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713462

Individualizing treatment of patients with myeloma in the era of novel agents.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713462

Improved survival in multiple myeloma and the impact of novel therapies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713462

International uniform response criteria for multiple myeloma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713462

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713462

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713462

Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713462

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713462

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713462

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713462

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2713462

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

3 September 2018

1 reference

12 December 2020

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

12 December 2020

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

1 reference

12 December 2020

Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials

1 reference

12 December 2020

An internationally recognized uniform cytogenetic classification system is needed for multiple myeloma

1 reference

12 December 2020

Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1)

1 reference

12 December 2020

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

12 December 2020

Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma

1 reference

12 December 2020

Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation

1 reference

12 December 2020

10.1182/BLOOD-2009-01-202010

Identifiers

DOI

1 reference

19 August 2017

1 reference

19 August 2017

1 reference

PMCID

2713462